Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365266 | 0.89 | GRIN2B (0.38) | GRIN2BNPC1SMN1; SMN2FYNRIPK1 | |
| SCHEMBL19364921 | 0.89 | KIF18A (0.38) | GRIN2BNPC1SMN1; SMN2FYNKIF18A | |
| SCHEMBL19670464 | 0.85 | MAPT (0.40) | GRIN2BNPC1SMN1; SMN2FYNKIF18A | |
| SCHEMBL20631868 | 0.85 | KIF18A (0.33) | GRIN2BNPC1KIF18ARAB9A | |
| SCHEMBL16776069 | 0.84 | CA2 (0.39) | GRIN2BNPC1SMN1; SMN2FYNKIF18A | |
| SCHEMBL19669976 | 0.83 | HTR2A (0.52) | NPC1SMN1; SMN2FYNRIPK1CA2 | |
| SCHEMBL19670654 | 0.81 | CA2 (0.42) | NPC1SMN1; SMN2FYNCA2CA9 | |
| SCHEMBL19365537 | 0.81 | CA2 (0.43) | NPC1SMN1; SMN2RIPK1CA2CA9 | |
| SCHEMBL17623988 | 0.80 | NPC1 (0.37) | GRIN2BNPC1SMN1; SMN2FYNRIPK1 | |
| SCHEMBL12654500 | 0.79 | CA2 (0.44) | NPC1SMN1; SMN2CA2CA9HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRIN2B 4510/4885NPC1 3380/4885SMN1; SMN2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.